We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Bristol-Myers Squibb Company et al v. Mylan Pharmaceuticals Inc.

Track this case

Case overview

Case Number:




Nature of Suit:


35:271 Patent Infringement


Leonard P. Stark



Sectors & Industries:

  1. October 18, 2018

    Bristol-Myers, Pfizer's Blood Thinner IP Suit Axed Over Venue

    A Delaware federal judge tossed a lawsuit filed by Bristol-Myers Squibb Co. and Pfizer Inc. seeking to block Mylan Pharmaceuticals Inc. from making a generic version of their patented blood thinner Eliquis, finding on Thursday that the suit was filed in the wrong venue in light of the U.S. Supreme Court's TC Heartland ruling.

  2. September 18, 2017

    3 Takeaways From Delaware's TC Heartland Venue Guidance

    The District of Delaware's chief judge recently held in two rulings that companies must have permanent ties to the state to face patent suits there following the U.S. Supreme Court's TC Heartland ruling, and his analysis could keep many generic-drug cases in his court. Here's what attorneys can learn from the decisions.

  3. September 12, 2017

    Del. Chief Judge Sets Post-TC Heartland Venue Guidelines

    The District of Delaware’s chief judge said Monday that after a recent U.S. Supreme Court ruling, companies must have a permanent and physical presence in the state to be sued there for patent infringement, so he transferred one case and ordered further discovery in another.